Sorry, you need to enable JavaScript to visit this website.

Skip to main content


Руководство отделением Cardiovascular & Metabolism

Наш талант


Д-р Джеймс Ф. Лист (James F. List), Ph.D., руководитель Глобальной терапевтической области «Сердечно-сосудистые и метаболические заболевания», возглавляет глобальную группу, занимающуюся созданием новых решений для совершенствования лечения сердечно-сосудистых заболеваний и сахарного диабета, а также ранней диагностики и лечения заболеваний. Джим отвечает за все стадии исследования и разработок для портфеля продуктов «Янссен» CVM, в том числе, за открытие новых лекарств, клиническую разработку и сторонние передовые разработки. Джим пришел работать в «Янссен» в 2014 г.

До начала работы в «Янссен» Джеймс работал в компании «Бристол-Майерс Сквибб» (Bristol-Myers Squibb») в должности вице-президента отдела разработок по сахарному диабету, где отвечал за совместное с «АстраЗенека» (AstraZeneca») предприятие по сахарному диабету.

На более ранних этапах своей карьеры Джеймс преподавал в Гарвардской медицинской школе в Бостоне, штат Массачусетс, США, имел медицинскую сферу ответственности в общей эндокринологии и эндокринологии щитовидной железы. Он окончил Стэнфордский университет, город Стэнфорд, штат Калифорния, США, и получил квалификацию врача и степень Ph.D. в Университете Миннесоты, город Миннеаполис, штат Миннесота, США. Джим прошел медицинское обучение в Бригамской женской больнице в Бостоне, Бостонской детской больнице и многопрофильной больнице Массачусетса, город Бостон, штат Массачусетс, США, и получил профессиональный сертификат по терапии внутренних болезней, педиатрии и эндокринологии.

Д-р Джеймс Ф. Лист, Ph.D.

Руководитель Глобальной терапевтической области «Сердечно-сосудистые и метаболические заболевания»

Calvin Schmidt is Global Commercial Strategy Leader (GCSL) for the Cardiovascular & Metabolism (CVM) therapeutic area and the GCSL for the newly created Johnson & Johnson Innovation World Without Disease Accelerator (WWDA).

CVM is maximizing the value of pipeline and marketed assets and developing innovative solutions for patients, providers and healthcare systems globally by working closely with R&D and BD toward the goal of longer, healthier lives for patients with the world’s most common chronic diseases.

WWDA strengthens Johnson & Johnson’s focus on creating solutions that eliminate disease through early detection, prevention, interception and cure. The WWD Accelerator will identify innovation wherever it originates, internally and externally; leverage relevant capabilities and competencies; build strategic alliances; and seed transformative growth opportunities, by working closely with R&D, BD and Innovation centers across the enterprise.

Prior to this role, he was President of Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, where he led the growth of a business that is making a significant difference for patients suffering from cardiovascular and metabolic diseases. In addition, with extensive international and emerging market experience, Calvin also oversaw the strategic management of Janssen’s portfolio of products in Puerto Rico.

Previously, Calvin was Worldwide Vice President, Human Resources, for the Johnson & Johnson Group of Consumer Companies, a member of the Consumer Group Operating Committee, and a member of the Johnson & Johnson Enterprise Human Resources Executive Committee and served as the first President of Wellness & Prevention, Inc., a Johnson & Johnson company, focused on helping organizations prevent chronic disease and sustain good health for their employees and members.

Other roles at Johnson & Johnson included General Manager, Johnson & Johnson Merck Joint Venture and Global Vice President, Marketing and Sales, for McNeil Nutritionals. Before joining Johnson & Johnson, Calvin was with Mars, Inc. for nearly 15 years, holding domestic and international leadership positions in operations, R&D, product development, marketing and general management.

In September 2017, Calvin was appointed to represent Johnson & Johnson on the Healthcare Leadership Council (HLC), a coalition of top executives from companies representing many sectors in the U.S. health system. In January 2015, he was named to the American Diabetes Association (ADA) Board of Directors, underscoring his dedication to combat the growing epidemic of diabetes; in 2016, he was named Chair of the ADA’s Audit Committee and in 2017 he was also named Chair of the ADA’s CEO search committee.

Calvin holds Master of Business Administration in Marketing and Finance from Capital University in Columbus, Ohio, and a Bachelor of Engineering in Electrical Engineering from Vanderbilt University.

Calvin W. Schmidt

Global Commercial Strategy Leader, Cardiovascular & Metabolism